Brazos Neuroscience provides the Neural‑Injury Assessment Test™, a proprietary blood‑based diagnostic that objectively detects mild‑to‑moderate traumatic brain injury (mmTBI) in the post‑acute or chronic phase, even up to five years after injury. The test analyzes specific blood and genetic biomarkers from a small, mobile‑collected sample and delivers a quantitative positive/negative result with prognosis in 7‑10 days, enabling clinicians to confirm symptoms and monitor treatment progress.
Funding
Funding not disclosed
Founders
Product
Problem
Diagnosing mild-to-moderate traumatic brain injury (mmTBI) in the post‑acute or chronic phase is difficult because symptoms are subjective and there are no widely accepted objective tests that can be performed long after the injury.
Solution
Brazos Neuroscience’s Neural‑Injury Assessment Test™ provides an objective, laboratory‑based diagnosis of mmTBI using a small blood sample. The test measures a panel of blood and genetic biomarkers associated with neuronal and glial damage, delivering a quantitative positive/negative result and a prognosis estimate within 7–10 days. A mobile phlebotomy service collects specimens nationwide, enabling testing at any time from weeks to over five years post‑injury. Results are presented in a clear report that clinicians can use to confirm patient symptoms, assess injury severity, and monitor response to treatment over time.
Target Audience
Primary customers are medical providers who manage concussion and TBI patients, including neurologists, neurosurgeons, physiatry specialists, primary care physicians, and sports medicine clinicians.
Features
- Proprietary biomarker panel combining blood proteins and genetic markers linked to brain injury
- Mobile specimen collection with nationwide phlebotomy, scheduled within 24–48 hours of request
- CLIA‑certified laboratory developed test with reported 99 % sensitivity and 93 % specificity for neuronal/glial damage
- Quantitative report delivering a simple positive/negative value and prognostic outlook for symptom persistence
- Validated for use up to and beyond five years after injury, with optimal baseline timing at 3 weeks post‑event and again after 6 months if symptoms persist
- Compatible with standard clinical ordering workflows; requires a licensed provider order (e.g., neurologist, primary care, physiatrist)